Stockscreener 앱 받기
0.00
100.00%
-13.60
시간 외 거래:
13.26
13.26
+
전일 마감가:
$13.60
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$17.96M
수익:
$40.93M
순이익/손실:
$-23.82M
주가수익비율:
0.00
EPS:
-18.71
순현금흐름:
$-37.87M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$18.68
Pieris Pharmaceuticals Inc Stock (PIRS) Company Profile
명칭
Pieris Pharmaceuticals Inc
전화
857-246-8998
주소
225 FRANKLIN STREET, BOSTON, MA
PIRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PIRS
Pieris Pharmaceuticals Inc
|
0.00 | 17.96M | 40.93M | -23.82M | -37.87M | -18.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Pieris Pharmaceuticals Inc Stock (PIRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-09 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-26 | 개시 | Stifel | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-02-05 | 개시 | TD Cowen | Buy |
| 2024-12-26 | 개시 | H.C. Wainwright | Buy |
| 2024-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 개시 | Jefferies | Buy |
| 2018-01-16 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-30 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-05 | 재개 | ROTH Capital | Buy |
| 2015-08-12 | 개시 | JMP Securities | Mkt Outperform |
| 2015-07-27 | 개시 | Oppenheimer | Outperform |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
모두보기
Pieris Pharmaceuticals Inc 주식(PIRS)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
(PVLA) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Ebenbuild Contributes Cutting-Edge Digital Lung Simulations to Pulmonary Fibrosis Drug Development - The Manila Times
Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021 - ACCESS Newswire
Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo
Asthma Market to Reach New Heights in Growth by 2034, - openPR.com
PALVELLA THERAPEUTICS, INC. SEC 10-K Report - TradingView
Palvella Therapeutics (PVLA) to Release Earnings on Monday - Defense World
(PVLA) Technical Data - news.stocktradersdaily.com
Shane Olwill joins Asgard from Pieris - The Pharma Letter
Public-Private Collaborations Drive Advancements In Anemia And Blood Disorder Drug Development: Key Trend T... - WhaTech
Pieris Pharmaceuticals stock soars to 52-week high of $29.01 - Investing.com
HER2+ Gastric Cancer Market to Witness Upsurge in Growth During the Forecast Period (2024-2034), Examine DelveInsight - The Globe and Mail
Pieris Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Pieris Pharmaceuticals stock hits 52-week high at $22.56 By Investing.com - Investing.com Canada
Pieris Pharmaceuticals stock hits 52-week high at $22.56 - Investing.com
Pieris Pharmaceuticals to Host Full-Year 2019 Investor Call and Corporate Update on March 12, 2020 - ACCESS Newswire
Pieris Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference - ACCESS Newswire
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MSN
Pieris Pharmaceuticals to Host Third Quarter 2020 Investor Call and Corporate Update on November 4, 2020 - ACCESS Newswire
Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update - ACCESS Newswire
Canaccord Genuity Initiates Palvella Therapeutics at Buy With $39 Price Target -February 20, 2025 at 07:44 am EST - Marketscreener.com
Palvella Therapeutics closes on Pieris merger; completes nearly $80M private placement - Pennsylvania Business Report -
TD Cowen Initiates Palvella Therapeutics at Buy With $44 Price Target -February 05, 2025 at 07:50 am EST - Marketscreener.com
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific - ACCESS Newswire
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential - ACCESS Newswire
Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor - ACCESS Newswire
Research Analysts Issue Forecasts for PVLA FY2025 Earnings - Defense World
Palvella reports positive phase 2 study on QTORIN rapamycin for rare skin disease - Investing.com India
Palvella reports positive phase 2 study on QTORIN rapamycin for rare skin disease By Investing.com - Investing.com South Africa
StockNews.com Begins Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS) - Defense World
Pieris Pharmaceuticals (NASDAQ:PIRS) Now Covered by Analysts at StockNews.com - Defense World
Palvella Therapeutics stock gains attention with Phase 3 trial data expected in early 2026 - Investing.com Canada
Pieris Pharmaceuticals (NASDAQ:PIRS) Coverage Initiated at StockNews.com - Defense World
Twelve option delistings on December 23rd - TipRanks
Pieris Pharmaceuticals: Q1 Earnings Snapshot - Marketscreener.com
Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical - VISTA.Today
Palvella therapeutics director George Jenkins acquires $51,720 in shares By Investing.com - Investing.com Canada
Palvella therapeutics director George Jenkins acquires $51,720 in shares - Investing.com
Pieris Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2021 - Marketscreener.com
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific - Marketscreener.com
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 - Marketscreener.com
Pieris Pharmaceuticals, Inc. Announces Management Changes - Marketscreener.com
Pieris Pharmaceuticals, Inc. Appoints Julian Adams to its Board of Directors - Marketscreener.com
Pieris Pharmaceuticals, Inc. Appoints Claude Knopf as Senior Vice President and Chief Business Officer - Marketscreener.com
After losing AstraZeneca collab, Boston biotech opts for reverse merger - The Business Journals
Palvella Therapeutics Closes Merger with Pieris Pharmaceuticals - citybiz
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346) - Marketscreener.com
Pieris Pharmaceuticals: Q3 Earnings Snapshot - Marketscreener.com
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc.PIRS - Marketscreener.com
Pieris Pharmaceuticals Inc (PIRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.47%
2.63%
자본화:
|
볼륨(24시간):